Hartmann + Glucose, Viaflo

Viaflo (Hartmann + Glucose) is an intravenous solution that combines potassium chloride, sodium chloride, calcium chloride dihydrate, glucose, and sodium lactate. It is supplied as a sterile, ready‑to‑use fluid for infusion. The formulation is designed to replace extracellular fluid volume and restore electrolyte balance in patients requiring fluid therapy. Viaflo is marketed in the European Union and is available by prescription only for clinical use in hospital settings.

Viaflo is indicated for situations where rapid fluid and electrolyte replacement is required.

- Rehydration of patients with moderate to severe dehydration due to gastrointestinal losses, burns, or fever. - Treatment of hypovolemia resulting from trauma, surgery, or hemorrhage. - Maintenance of electrolyte balance during prolonged fasting, postoperative recovery, or intensive care. - Support of metabolic needs in patients receiving parenteral nutrition who require additional glucose and electrolytes. - Correction of mild to moderate electrolyte disturbances such as hyponatremia, hypokalemia, or hypocalcemia. - Provision of isotonic fluid for patients undergoing major surgery to maintain intravascular volume.

Side effects associated with intravenous administration of Viaflo are generally related to the solution’s electrolyte composition and infusion characteristics.

Common: - Mild irritation or pain at the infusion site. - Transient increase in blood glucose levels. - Slight nausea or vomiting. - Temporary electrolyte shifts causing mild muscle cramps. - Headache or dizziness during infusion. - Localized redness or swelling at the catheter insertion site.

Serious: - Hyperkalemia leading to cardiac arrhythmia. - Hypernatremia or hyperchloremia with neurologic symptoms. - Severe allergic reaction or anaphylaxis. - Volume overload causing pulmonary edema. - Acute renal impairment due to electrolyte imbalance. - Severe metabolic acidosis secondary to lactate accumulation.

When prescribing or administering Viaflo, clinicians should evaluate patient-specific factors and monitor relevant parameters to minimize risk.

- Assess baseline serum electrolytes, renal function, and cardiac status before initiation. - Adjust infusion rate in patients with heart failure or compromised pulmonary function. - Use caution in individuals with diabetes or impaired glucose tolerance due to the glucose content. - Avoid rapid large-volume infusions in neonates and small children without appropriate dosing guidelines. - Monitor fluid balance, weight, and urine output throughout therapy. - Discontinue or modify therapy if signs of electrolyte overload or acid‑base disturbance appear.

Viaflo may interact with other intravenous or oral agents that influence electrolyte levels, fluid balance, or cardiac conduction.

Avoid: - Concurrent administration of potassium‑sparing diuretics or ACE inhibitors in patients at risk for hyperkalemia. - High‑dose sodium bicarbonate solutions that could exacerbate hypernatremia or volume overload.

Use with caution: - Loop or thiazide diuretics that may alter sodium and potassium balance. - Insulin therapy, which can shift glucose and potassium intracellularly. - Blood products or albumin solutions that contribute additional electrolytes. - Medications that prolong the QT interval, as electrolyte disturbances can increase arrhythmia risk. - Vasopressor agents, because fluid shifts may affect hemodynamic response.